Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Micafungin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | UBE2M | P61081 | 1/20 | 1.00 |
| ▸ | NEDD8 | Q15843 | 1/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Micafungin SCHEMBL31615511 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL37671 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL13575751 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL16550435 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL19600986 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL23001458 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL14380016 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL14403608 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL14071559 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 | |
| Micafungin SCHEMBL11893279 | 1.00 | ESR1 (1.00) | ESR1PGRADORA3CHRM1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458189-B2 | Cytoprotective drugs | BALMES TRANSPLANTATION (FR) | 2022-10-04 | — | — | US | disclosed |
| CN-109956994-B | Preparation method of micafungin sodium salt | 江苏豪森药业集团有限公司 | 2022-09-30 | — | — | CN | disclosed |
| US-20200397854-A1 | NOVEL CYTOPROTECTIVE DRUGS | BALMES TRANSPLANTATION (FR) | 2020-12-24 | — | — | US | disclosed |
| WO-2020229761-A1 | NOVEL CYTOPROTECTIVE MEDICAMENTS | BALMES TRANSPLANTATION (FR) | 2020-11-19 | — | — | WO | disclosed |
| EP-3710038-A1 | NOVEL CYTOPROTECTIVE DRUGS | Balmes Transplantation (FR) | 2020-09-23 | — | — | EP | disclosed |
| CN-111405904-A | Novel cytoprotective agents | 巴勒姆移植 | 2020-07-10 | — | — | CN | disclosed |
| US-20160264628-A1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | SANDOZ AG (CH) | 2016-09-15 | — | — | US | disclosed |
| EP-2694531-B1 | METHODS FOR MANUFACTURING AN ANTIFUNGAL AGENT | XELLIA PHARMACEUTICALS APS (DK) | 2016-09-14 | — | — | EP | disclosed |
| EP-2763971-B1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | SANDOZ AG (CH) | 2016-06-08 | — | — | EP | disclosed |
| WO-2016056023-A2 | INTERMEDIATES AND PROCESSES TO PREPARE MICAFUNGIN | ALAPARTHI LAKSHMI PRASAD (IN) | 2016-04-14 | — | — | WO | disclosed |
| US-8981055-B2 | Methods for manufacturing an antifungal agent | XELLIA PHARMACEUTICALS APS (DK) | 2015-03-17 | — | — | US | disclosed |
| US-20140371423-A1 | METHOD FOR PURIFICATION OF MICAFUNGIN | XELLIA PHARMACEUTICALS APS (DK) | 2014-12-18 | — | — | US | disclosed |
| US-20140371422-A1 | METHODS FOR MANUFACTURING AN ANTIFUNGAL AGENT | XELLIA PHARMACEUTICALS APS (DK) | 2014-12-18 | — | — | US | disclosed |
| US-20140329989-A1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | SANDOZ AG (CH) | 2014-11-06 | — | — | US | disclosed |
| CN-103917531-A | Preparation of micafungin intermediates | SANDOZ AG | 2014-07-09 | — | — | CN | disclosed |
| CN-103533995-A | Method for purification of micafungin | XELLIA PHARMACEUTICALS APS | 2014-01-22 | — | — | CN | disclosed |
| CN-103492409-A | Methods for manufacturing an antifungal agent | XELLIA PHARMACEUTICALS APS | 2014-01-01 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7375081-B2 | Therapeutic combination of a pneumocandin derivative and an antifungal agent | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264628-A1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | DPM1, ERG28, MAN2B1 | ESR1 4883/4885PGR 4707/4885ADORA3 4256/4885 |
| US-20200397854-A1 | NOVEL CYTOPROTECTIVE DRUGS | BAD, AIFM1, CASP3 | ESR1 4360/4885PGR 4627/4885ADORA3 1915/4885 |
| US-20140371422-A1 | METHODS FOR MANUFACTURING AN ANTIFUNGAL AGENT | DPM1, ERG28, MANBA | ESR1 4874/4885PGR 4711/4885ADORA3 3938/4885 |
| US-20140329989-A1 | PREPARATION OF MICAFUNGIN INTERMEDIATES | DPM1, ERG28, MAN2B1 | ESR1 4883/4885PGR 4707/4885ADORA3 4256/4885 |
| US-20140371423-A1 | METHOD FOR PURIFICATION OF MICAFUNGIN | MANBA, DPM1, MAN2A1 | ESR1 4885/4885PGR 4862/4885ADORA3 4648/4885 |
| US-11458189-B2 | Cytoprotective drugs | BAD, AIFM1, CASP3 | ESR1 3684/4885PGR 4363/4885ADORA3 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.